1. Home
  2. OMCL vs COGT Comparison

OMCL vs COGT Comparison

Compare OMCL & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OMCL
  • COGT
  • Stock Information
  • Founded
  • OMCL 1992
  • COGT 2014
  • Country
  • OMCL United States
  • COGT United States
  • Employees
  • OMCL N/A
  • COGT N/A
  • Industry
  • OMCL Computer Manufacturing
  • COGT Biotechnology: Pharmaceutical Preparations
  • Sector
  • OMCL Technology
  • COGT Health Care
  • Exchange
  • OMCL Nasdaq
  • COGT Nasdaq
  • Market Cap
  • OMCL 1.3B
  • COGT 1.1B
  • IPO Year
  • OMCL 2001
  • COGT 2018
  • Fundamental
  • Price
  • OMCL $27.56
  • COGT $11.00
  • Analyst Decision
  • OMCL Buy
  • COGT Strong Buy
  • Analyst Count
  • OMCL 6
  • COGT 9
  • Target Price
  • OMCL $44.83
  • COGT $19.38
  • AVG Volume (30 Days)
  • OMCL 421.9K
  • COGT 4.8M
  • Earning Date
  • OMCL 07-31-2025
  • COGT 08-05-2025
  • Dividend Yield
  • OMCL N/A
  • COGT N/A
  • EPS Growth
  • OMCL N/A
  • COGT N/A
  • EPS
  • OMCL 0.45
  • COGT N/A
  • Revenue
  • OMCL $1,135,755,000.00
  • COGT N/A
  • Revenue This Year
  • OMCL $3.84
  • COGT N/A
  • Revenue Next Year
  • OMCL $3.98
  • COGT N/A
  • P/E Ratio
  • OMCL $60.91
  • COGT N/A
  • Revenue Growth
  • OMCL 3.00
  • COGT N/A
  • 52 Week Low
  • OMCL $22.66
  • COGT $3.72
  • 52 Week High
  • OMCL $55.75
  • COGT $12.61
  • Technical
  • Relative Strength Index (RSI)
  • OMCL 38.75
  • COGT 87.74
  • Support Level
  • OMCL $28.81
  • COGT $7.07
  • Resistance Level
  • OMCL $30.19
  • COGT $10.23
  • Average True Range (ATR)
  • OMCL 0.86
  • COGT 0.66
  • MACD
  • OMCL -0.08
  • COGT 0.37
  • Stochastic Oscillator
  • OMCL 0.00
  • COGT 99.89

About OMCL Omnicell Inc. ($0.001 par value)

Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: